Skip to main content
. 2020 Feb 29;21(2):e32. doi: 10.4142/jvs.2020.21.e32

Table 1. Mean (± SD) pharmacokinetic parameters of levofloxacin in plasma following I/V, I/M or S/C administration to rabbits at a dose of 5 mg/kg bodyweight.

PK parameters Units I/V (n = 6) I/M (n = 6) S/C (n = 4)
AUC0−last mg*h/L 9.03 ± 2.66 9.07 ± 1.80 9.28 ± 1.56
AUC0−inf mg*h/L 9.08 ± 2.64 9.07 ± 1.80 9.31 ± 1.50
AUMC0−last mg*h*h/L 22.93 ± 12.46 37.87 ± 18.35* 36.62 ± 17.35
AUMC0−inf mg*h*h/L 23.64 ± 12.17 37.89 ± 18.34* 36.98 ± 16.82
Cmax μg/mL N/A 3.33 ± 0.39 2.91 ± 0.56
Cfirst μg/mL 7.13 ± 1.47 N/A N/A
tmax MEDIAN h N/A 0.50 (0.08–0.75)† 0.75
t1/2λz HM h 2.06 ± 0.18 2.01 ± 0.24 1.80 ± 0.14
λz 1/h 0.34 ± 0.03 0.34 ± 0.04 0.39 ± 0.03
MRT0−last HM h 2.19 ± 0.83 3.75 ± 1.16* 3.44 ± 1.31
MRT0−inf HM h 2.27 ± 0.80 3.75 ± 1.16* 3.52 ± 1.25
MAT HM h N/A 1.29 ± 0.61 0.45 ± 1.47
Cl mL/g*h 0.60 ± 0.18 N/A N/A
Cl/F mL/g*h N/A 0.57 ± 0.11 0.55 ± 0.10
Vss mL/g 1.37 ± 0.39 N/A N/A
Varea/F mL/g N/A 1.66 ± 0.34 1.42 ± 0.18
F % N/A 105.69 ± 27.50 118.93 ± 40.51

PK, pharmacokinetic; AUC0−last, area under the plasma-concentration time curve from zero to the last quantified sampling point time; AUC0-inf, area under the plasma-concentration time curve from zero extrapolated to infinity; AUMC0−last, area under the first moment curve from zero to the last quantified sampling point time; AUMC0−inf, area under the first moment curve from zero extrapolated to infinity; Cmax, maximum plasma drug concentration; Cfirst, concentration at first sample collection point; tmax, time of the maximum plasma concentration; t1/2λz, half-life of the elimination part of the curve; λz, slope of the elimination part of the curve; MRT0−last, mean residence time from zero to the last quantified sampling point time; MRT0−inf, mean residence time from zero extrapolated to infinity; MAT, mean absorption time; Cl, total plasma clearance; Cl/F, plasma clearance corrected to the bioavailability; Vss, volume of distribution at steady-state; Varea/F, volume of distribution corrected to the bioavailability; n, number of experimental animals receiving levofloxacin via the corresponding route of administration; I/V, intravenous; I/M, intramuscular; S/C, subcutaneous; N/A, not applicable; HM, harmonic mean.

*Significantly different from I/V administration (p < 0.05); †Range reported.